No Data Yet
GeoVax announced its COVID-19 vaccine, GEO-CM04S1, showed superior T-cell responses in CLL patients versus Pfizer's mRNA vaccine. The trial's independent monitoring board recommended stopping the comparator arm, signaling a significant clinical validation for GeoVax's platform.
Merck's recent stock outperformance highlights a broader pharmaceutical sector trend, as giants like Pfizer aggressively pivot to new growth areas like oncology and obesity to navigate a post-COVID landscape and looming patent cliffs.
A new Centers for Disease Control and Prevention (CDC) report validates the effectiveness of 2024–2025 COVID-19 vaccines in children. This data provides a strong, evidence-based counterpoint to vaccine hesitancy amid ongoing public health challenges like the measles outbreak in South Carolina.
Pfizer is executing a major strategic pivot away from its COVID-19 focus, investing heavily in the high-growth obesity drug market and advancing its oncology pipeline to build new, sustainable revenue streams for the long term.